CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)		12 Months Ended
		Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development		$ 31,008,151	$ 21,995,291
Acquired in-process research and development		0	5,103,753
General and administrative		11,008,900	9,662,875
Total operating expenses		42,017,051	36,761,919
Loss from operations		(42,017,051)	(36,761,919)
Other income (expense):
Interest income		501,228	22,707
Interest expense		(2,667,289)	(47,188)
Loss on extinguishment of convertible note payable		(20,303)	0
Change in fair value of derivative liability		437,000	7,000
Total other income (expense), net		(1,749,364)	(17,481)
Loss before income taxes		(43,766,415)	(36,779,400)
Income tax benefit		0	0
Net loss		$ (43,766,415)	$ (36,779,400)
Net loss per common share, basic (in dollars per share)	[1]	$ (3.38)	$ (3.03)
Net loss per common share, diluted (in dollars per share)	[1]	$ (3.38)	$ (3.03)
Weighted-average common shares, basic (in shares)	[1]	12,955,577	12,155,429
Weighted-average common shares, diluted (in shares)	[1]	12,955,577	12,155,429

[1] 1Amounts have been retroactively restated to reflect the 1-for-20 reverse stock-split effected on October 17, 2022 (see Note 1)